A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

The company estimates that its install base surpassed 15,000 by the end of last year, leading to sales of more than $20 million in the fourth quarter.

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

has announced that the US Food and Drug Administration (FDA) has cleared Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in those six years old ...

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes drugs, challenges facing the World Health Organization after funding cuts, lawsuits regarding insulin prices,

It also caps insulin ... could impact drug prices by curbing research into cost-reduction models and suggests that reducing drug prices is not a priority for the Trump administration.

The final proposed model would have had Medicare pay less for drugs that receive accelerated approvals from the Food and Drug Administration (FDA ... such as the $35 per month cap on insulin costs, were not affected by Trump’s executive order.

On the first day of his second term, President Donald Trump signed an executive order revoking dozens of the Biden administration ... model capping insulin costs at $35 per month for people on participating Medicare Part D prescription drug plans.

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ revenue jump was largely due to the US Food and Drug Administration (FDA) approval of its iLet insulin delivery system for type 1 diabetes in mid-2023.

Shares in the Irvine-based medical device company rose 29% to $23.64 and a $975 million market within the first three hours of trading.

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies show it lowers kidney-related complications by 24 per cent. This offers new hope for patients,

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.